David Roig Carles
About David Roig Carles
David Roig Carles is a scientist currently serving as a Postdoctoral Researcher at The Open University in Milton Keynes, England. He has extensive experience in cancer research, particularly in cell communication mechanisms and the development of therapies for advanced prostate cancer and pediatric brain gliomas.
Work at Adaptimmune
David Roig Carles has been employed as a Scientist at Adaptimmune since 2021. His role involves conducting research focused on the mechanisms of cell communication, particularly examining exosomes at the blood-brain barrier during inflammation. This position builds on his extensive background in cancer research and molecular biology.
Current Position at The Open University
In addition to his role at Adaptimmune, David Roig Carles has been a Postdoctoral Researcher at The Open University since 2021. His work in this position continues to leverage his expertise in cancer models and cell biology, contributing to ongoing research initiatives within the institution.
Education and Expertise
David Roig Carles earned his Doctor of Philosophy (PhD) in Cell Biology and Inflammation from The Open University, completing his studies from 2015 to 2021. Prior to this, he obtained a Master's degree in Molecular Medicine from Cranfield University in 2015. He also holds a degree in Biomedicine from Universitat Politècnica de València, which he completed in 2014.
Previous Experience at The Open University
Before his current roles, David Roig Carles held several positions at The Open University. He served as a Research Assistant from 2020 to 2021 and as a Laboratory Technician from 2019 to 2020. Additionally, he worked on a Master Research Project in 2015, which provided him with foundational experience in research methodologies.
Research Focus and Contributions
David Roig Carles has experience utilizing both in vitro and in vivo cancer models for research purposes. His work includes characterizing novel long non-coding RNAs and designing anti-sense oligonucleotide therapies aimed at advanced prostate cancer and pediatric brain gliomas. This research contributes to the understanding of cancer biology and potential therapeutic approaches.